|
Market Closed -
London S.E.
20:35:10 29/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 203.50 GBX | 0.00% |
|
+2.26% | +58.98% |
| 09-24 | Diaceutics PLC And Syndax Pharmaceuticals, Inc. Expand Multi-Year Relay Partnership | CI |
| 09-22 | EARNINGS: Origin Enterprises beats operating profit target | AN |
Company Valuation: Diaceutics PLC
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 85.75 | 63.68 | 73.32 | 106.1 | 108.7 | 172.7 | - | - |
| Change | - | -25.74% | 15.14% | 44.67% | 2.47% | 58.94% | - | - |
| Enterprise Value (EV) 1 | 66.08 | 43.84 | 56.65 | 93.32 | 101.3 | 165 | 162.3 | 157.3 |
| Change | - | -33.66% | 29.24% | 64.73% | 8.6% | 62.83% | -1.62% | -3.1% |
| P/E | - | 89.9x | -42x | -62.1x | - | - | - | - |
| PBR | - | 1.53x | 1.8x | 2.66x | 2.67x | 4.19x | 3.74x | 3.09x |
| PEG | - | - | 0x | 25.71x | - | - | - | - |
| Capitalization / Revenue | 6.15x | 3.26x | 3.09x | 3.3x | 2.83x | 3.7x | 3.07x | 2.57x |
| EV / Revenue | 4.74x | 2.25x | 2.39x | 2.9x | 2.64x | 3.53x | 2.88x | 2.34x |
| EV / EBITDA | 28.1x | 12.2x | 24x | 22.2x | 13.4x | 16.2x | 11.8x | 8.67x |
| EV / EBIT | 120x | 76.4x | -18.8x | -38x | 57.5x | 51.6x | 23.9x | 15.3x |
| EV / FCF | -13.1x | 194x | -16x | -23.4x | -19.2x | 262x | 58.3x | 31.7x |
| FCF Yield | -7.61% | 0.52% | -6.26% | -4.27% | -5.2% | 0.38% | 1.72% | 3.15% |
| Dividend per Share 2 | - | - | - | - | - | - | - | 1 |
| Rate of return | - | - | - | - | - | - | - | 49.1% |
| EPS 2 | - | 0.0084 | -0.0207 | -0.0202 | - | - | - | - |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 13.94 | 19.5 | 23.7 | 32.16 | 38.44 | 46.72 | 56.34 | 67.09 |
| EBITDA 1 | 2.349 | 3.583 | 2.357 | 4.206 | 7.573 | 10.19 | 13.79 | 18.15 |
| EBIT 1 | 0.55 | 0.574 | -3.018 | -2.455 | 1.761 | 3.2 | 6.8 | 10.3 |
| Net income 1 | 0.561 | 0.724 | -1.746 | -1.703 | 0.097 | -1.1 | 2.85 | 6.05 |
| Net Debt 1 | -19.68 | -19.84 | -16.67 | -12.74 | -7.344 | -7.729 | -10.4 | -15.43 |
| Reference price 2 | 1.020 | 0.755 | 0.870 | 1.255 | 1.280 | 2.035 | 2.035 | 2.035 |
| Nbr of stocks (in thousands) | 84,069 | 84,339 | 84,274 | 84,515 | 84,912 | 84,886 | - | - |
| Announcement Date | 22/03/22 | 17/04/23 | 21/05/24 | 13/05/25 | 26/05/26 | - | - | - |
1GBP in Million2GBP
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | 3.53x | 16.2x | -.--% | 230M | |
| 31.97x | 16.49x | 23.44x | 0.67% | 745B | |
| 38.61x | 7.02x | 24.92x | 0.93% | 84.5B | |
| 24.28x | 4.84x | 10.55x | 0.67% | 72.73B | |
| 11.15x | 1.45x | 7.16x | 0.99% | 46.97B | |
| -86.29x | 19.02x | 46.14x | -.--% | 49.98B | |
| 43.54x | 1.67x | 9.37x | -.--% | 45.47B | |
| 21.16x | 3.57x | 8.47x | 1.49% | 33.97B | |
| 19.85x | 6.07x | 11.65x | -.--% | 25.99B | |
| 10.06x | 2.62x | 6.32x | -.--% | 25.45B | |
| Average | 12.70x | 6.63x | 16.42x | 0.48% | 113.02B | |
| Weighted average by Cap. | 25.25x | 12.98x | 21.37x | 0.64% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- DXRX Stock
- Valuation Diaceutics PLC
Select your edition
All financial news and data tailored to specific country editions
